Phospho-PLCG2 (Y1217) Antibody

What is PLCG2 and what is the significance of its phosphorylation at Y1217?

Phospholipase C-gamma 2 (PLCG2) is a transmembrane signaling enzyme that catalyzes the conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), using calcium as a cofactor. This enzyme plays a crucial role in signal transduction, particularly in hematopoietic cells such as B cells, mast cells, macrophages, natural killer cells, and platelets . Phosphorylation at tyrosine 1217 (Y1217) represents a critical activation event that occurs in response to B-cell receptor engagement and has been implicated in multiple immune signaling pathways . Unlike other phosphorylation sites, Y1217 phosphorylation appears to serve specific signaling functions that are independent of the enzyme's lipase activity, suggesting a complex regulatory mechanism in immune cell function .

How does phosphorylation at Y1217 differ from phosphorylation at other tyrosine residues of PLCG2?

Phosphorylation of PLCG2 occurs at multiple tyrosine residues, including Y753, Y759, and Y1217, each with distinct characteristics:

Research has demonstrated that in cells stimulated maximally via the B-cell receptor, the extent of phosphorylation at Y1217 is approximately three times that observed at Y753 or Y759 . Additionally, while Y753 and Y759 phosphorylation correlates with PLCG2 lipase activity, Y1217 phosphorylation does not, suggesting a distinct functional role . Another key difference is that phosphorylation at Y1217 and phosphorylation at Y753/Y759 occur on different PLCG2 molecules, indicating separate pools of the protein may participate in different signaling pathways .

What is the role of PLCG2 Y1217 phosphorylation in microglia and neurodegenerative diseases?

Recent research has revealed an important role for PLCG2 Y1217 phosphorylation in microglia, particularly in the context of neurodegenerative diseases. Studies have shown that PLCG2 is phosphorylated at Y1217, rather than the canonical Y753 or Y759 residues, in response to oligomeric amyloid-β (Aβ) . This phosphorylation event is part of the TREM2 (Triggering Receptor Expressed on Myeloid cells 2) amyloid-β sensing pathway in microglia .

In TgCRND8 mouse models with homozygous R47H mutation or TREM2 knockout, reduced microglial density and diminished association with amyloid plaques have been observed. Importantly, the phosphorylation of PLCG2 at Y1217 was found to be proportional to plaque distance in wild-type TREM2 mice, but this relationship was lost in R47H or TREM2 knockout mice . This suggests that proper PLCG2 Y1217 phosphorylation is essential for normal microglial function in response to amyloid pathology.

Furthermore, in human iPSC-derived macrophages with the P522R PLCG2 variant, researchers observed increased duration (but not quantity) of Y1217 phosphorylation, enhanced phagocytosis of apoptotic neurons, and reduced pro-inflammatory cytokine secretion in response to LPS challenge . These findings indicate that PLCG2 Y1217 phosphorylation modulates microglial response to amyloid-β and may represent a therapeutic target for neurodegenerative diseases.

What are the molecular mechanisms underlying the Btk-independent phosphorylation of PLCG2 at Y1217?

The phosphorylation of PLCG2 at Y1217 exhibits a unique regulatory mechanism that is independent of Bruton's tyrosine kinase (Btk), unlike phosphorylation at Y753 and Y759 which are largely Btk-dependent . This distinction raises important questions about the alternative kinases responsible for Y1217 phosphorylation.

Experimental evidence from pharmacological inhibitor studies and RNA interference in Ramos cells has confirmed that while Btk plays a major role in phosphorylating Y753 and Y759, it has minimal involvement in Y1217 phosphorylation . The specific kinase(s) responsible for Y1217 phosphorylation remain under investigation. Potential candidates may include members of the Src family kinases or other non-receptor tyrosine kinases that are activated downstream of B-cell receptor engagement.

The signaling complexes involved in facilitating Y1217 phosphorylation likely differ from those mediating Y753/Y759 phosphorylation. Upon stimulation of B cells or TREM2/DAP12 receptor complexes, PLCG2 interacts with SYK, BTK, and BLNK (also called SLP-65), leading to the activation of its catalytic domain through phosphorylation at different sites, including Y1217 . This phosphorylation event appears to be part of a distinct signaling branch with its own functional consequences, separate from the lipase activity-related pathway.

How do PLCG2 genetic variants affect Y1217 phosphorylation and immune function?

Genetic variants of PLCG2 have been linked to various immune dysregulation syndromes and neurodegenerative diseases. Recent research has begun to elucidate how these variants specifically affect Y1217 phosphorylation:

Studies using isogenic human iPSC-derived macrophages have shown that the P522R PLCG2 variant, which is protective against Alzheimer's disease, exhibits increased duration of Y1217 phosphorylation without affecting the quantity . This enhanced signaling correlates with increased phagocytosis of apoptotic neurons and reduced pro-inflammatory cytokine secretion in response to LPS challenge .

In contrast, the R47H mutation in TREM2 disrupts the normal phosphorylation pattern of PLCG2 at Y1217 in response to amyloid-β stimulation. Quantification of pY1217 PLCG2 signal in microglia as a function of distance to plaque center revealed that this phosphorylation motif was proportional to plaque distance in wild-type TREM2 mice, but not in R47H or TREM2 knockout mice .

What is the relationship between PLCG2 Y1217 phosphorylation and calcium signaling in immune cells?

PLCG2 Y1217 phosphorylation plays a critical role in calcium signaling in immune cells, though through mechanisms distinct from those mediated by Y753/Y759 phosphorylation. Research has demonstrated that intracellular Ca²⁺ release in THP1 cells in response to Aβ oligomers is impaired when TREM2 is silenced by siRNA, indicating that the TREM2 pathway, which involves PLCG2 Y1217 phosphorylation, is reliant on calcium flux to facilitate its signaling response to Aβ oligomers .

The canonical signaling pathway involves PLCG2-mediated hydrolysis of PIP2 to generate the secondary messengers IP3 and DAG. IP3 then triggers the release of calcium from intracellular stores, leading to elevated cytoplasmic calcium concentrations. This calcium elevation promotes the activation of calcium-regulated transcription factors, including nuclear factor kappa B (NFKB) and nuclear factor of activated T-cells (NFAT) .

Although Y1217 phosphorylation does not directly correlate with PLCG2 lipase activity, it appears to be critical for specific calcium-dependent signaling pathways, particularly in the context of microglial responses to amyloid-β. This suggests that Y1217 phosphorylation might modulate calcium signaling through alternative mechanisms, possibly involving protein-protein interactions or regulation of other signaling components.

What are the optimal conditions for detecting PLCG2 Y1217 phosphorylation in different experimental systems?

Detecting PLCG2 Y1217 phosphorylation requires careful consideration of experimental conditions to achieve optimal results across different cell types and stimulation protocols:

For B cells, stimulation with an anti-IgM antibody has been shown to effectively induce PLCG2 Y1217 phosphorylation. In human B cell lymphoma Ramos cells, optimal results were obtained when cells were seeded at 400,000 cells/well in a half-area 96-well culture-treated plate in 25 μL complete culture medium, incubated for 3 hours at 37°C with 5% CO₂, and then stimulated with increasing concentrations of an anti-human IgM antibody for 5 minutes . Cells should be lysed with supplemented lysis buffer for 30 minutes at room temperature under gentle shaking to preserve phosphorylation states.

For microglia and macrophages, stimulation protocols may involve oligomeric Aβ or TREM2-activating antibodies. When performing immunohistochemistry of paraffin-embedded tissues (such as mouse spleen), microwave antigen retrieval with 10 mM Tris/EDTA buffer pH 9.0 is recommended before commencing with the IHC staining protocol .

How can researchers effectively validate the specificity of Phospho-PLCG2 (Y1217) antibodies?

Validating the specificity of Phospho-PLCG2 (Y1217) antibodies is crucial for ensuring reliable experimental results. Several complementary approaches are recommended:

• Positive and negative controls: Use Raji cells treated with pervanadate (a phosphatase inhibitor) as a positive control . For negative controls, use unstimulated cells or cells where PLCG2 has been knocked down using siRNA or CRISPR-Cas9.

• Phosphatase treatment: Split your samples and treat one set with lambda phosphatase to remove phosphorylation. A specific phospho-antibody should show dramatically reduced signal in the phosphatase-treated samples.

• Blocking peptide competition: The antibody can be pre-incubated with a synthetic phosphorylated peptide containing the Y1217 site (FLYD-pY-T) before application to samples. This should abolish specific binding if the antibody is truly specific .

• Comparative analysis with total PLCG2 antibody: Compare the signal obtained with the phospho-specific antibody to that obtained with a total PLCG2 antibody under both stimulated and unstimulated conditions. The phospho-specific signal should increase upon stimulation while the total PLCG2 signal remains constant .

• Western blot validation: Verify that the antibody detects a single band of approximately 150 kDa (the observed molecular weight of PLCG2) in Western blot applications .

The antibody should be affinity-purified from rabbit antiserum by affinity-chromatography using an epitope-specific immunogen, with purity greater than 95% as assessed by SDS-PAGE .

What experimental approaches can be used to study the functional consequences of PLCG2 Y1217 phosphorylation?

To investigate the functional significance of PLCG2 Y1217 phosphorylation, researchers can employ several complementary experimental approaches:

• Site-directed mutagenesis: Generate Y1217F mutants (where tyrosine is replaced by phenylalanine) to prevent phosphorylation at this site. Compare cellular responses between wild-type and mutant PLCG2 in reconstituted systems.

• Phosphomimetic mutations: Create Y1217E or Y1217D mutants (where tyrosine is replaced by glutamic acid or aspartic acid) to mimic constitutive phosphorylation. This approach can help identify downstream effects of this phosphorylation event.

• Proximity-based proteomics: Use BioID or APEX2 fused to wild-type or Y1217F mutant PLCG2 to identify proteins that differentially interact with PLCG2 depending on its Y1217 phosphorylation status.

• Calcium imaging: Measure intracellular calcium flux in cells expressing wild-type versus Y1217F PLCG2 in response to various stimuli. Research has shown that intracellular Ca²⁺ release in response to Aβ oligomers is impaired when TREM2 is silenced, suggesting a link between Y1217 phosphorylation and calcium signaling .

• Functional assays in relevant cell types:

  • In B cells: Measure proliferation, antibody production, and cytokine release

  • In microglia: Assess phagocytosis of Aβ, chemotaxis toward plaques, and inflammatory cytokine production

  • In macrophages: Evaluate phagocytosis of apoptotic neurons and response to inflammatory stimuli

• In vivo models: Utilize knock-in mice expressing Y1217F PLCG2 to study the impact on immune responses and, in the context of neurodegenerative disease models, on microglial responses to amyloid pathology.

How can HTRF technology be optimized for quantitative detection of PLCG2 Y1217 phosphorylation?

Homogeneous Time-Resolved Fluorescence (HTRF) technology offers a powerful approach for quantitative detection of PLCG2 Y1217 phosphorylation in a high-throughput format. To optimize this method:

• Cell preparation: For B cell lines such as Ramos, seed 400,000 cells/well in a half-area 96-well culture-treated plate in 25 μL complete culture medium and incubate for 3 hours at 37°C with 5% CO₂ before stimulation .

• Stimulation protocol: Stimulate cells with 5 μL of increasing concentrations of an anti-human IgM antibody for 5 minutes to induce a dose-dependent PLCG2 Y1217 phosphorylation .

• Lysis conditions: Lyse cells with 10 μL of supplemented lysis buffer #4 (4X) for 30 minutes at room temperature under gentle shaking to preserve phosphorylation states .

• Detection setup: Transfer 16 μL of cell lysate into a 384-well low volume white microplate and add 4 μL of the HTRF Phospho-PLCG2 (Y1217) or Total-PLCG2 detection reagents .

• Incubation time: For optimal signal-to-background ratio, incubate the plate overnight before measuring the HTRF signal .

• Controls and normalization: Always include unstimulated cells as negative controls and maximally stimulated cells (e.g., pervanadate-treated) as positive controls. For comparative studies, normalize phospho-PLCG2 (Y1217) signals to total PLCG2 to account for variations in protein expression.

• Assay validation: Verify assay performance by calculating Z' factor, which should be greater than 0.5 for a robust assay. Also, confirm that the HTRF signal increases in a dose-dependent manner with stimulation and correlates with Western blot results.

The HTRF-based detection offers several advantages over traditional Western blot, including higher throughput, greater sensitivity, and better quantification. The assay can be performed in either a two-plate protocol (for monitoring cell viability) or a single-plate protocol (for HTS applications), providing flexibility for different research needs .

How is Phospho-PLCG2 (Y1217) involved in the pathogenesis of neurodegenerative diseases?

PLCG2 Y1217 phosphorylation has emerged as a critical component in microglial responses to amyloid-β, with important implications for neurodegenerative diseases like Alzheimer's. Recent research has established that PLCG2 is phosphorylated at Y1217, not the canonical Y753 or Y759 residues, in response to oligomeric Aβ . This phosphorylation event is part of the TREM2 amyloid-β sensing pathway in microglia.

Quantitative analysis of pY1217 PLCG2 signal in microglia has shown that this phosphorylation is proportional to distance from amyloid plaque centers in wild-type TREM2 mice, but this relationship is disrupted in mice with TREM2 R47H mutation or TREM2 knockout . This finding suggests that proper PLCG2 phosphorylation at Y1217 is essential for normal microglial responses to amyloid pathology.

The P522R variant of PLCG2, which has been associated with protection against Alzheimer's disease, exhibits an increased duration of Y1217 phosphorylation in human iPSC-derived macrophages . This enhanced signaling correlates with functional changes, including increased phagocytosis of apoptotic neurons and reduced pro-inflammatory cytokine secretion in response to inflammatory stimuli .

These discoveries highlight the potential of targeting PLCG2 Y1217 phosphorylation as a therapeutic strategy for neurodegenerative diseases. Enhancing this phosphorylation event could potentially promote beneficial microglial functions while suppressing harmful inflammatory responses, mimicking the effects of the protective P522R variant.

What are the emerging techniques for studying PLCG2 Y1217 phosphorylation in complex tissues?

As research on PLCG2 Y1217 phosphorylation expands from cell culture systems to complex tissues, several emerging techniques offer new opportunities for investigation:

• Spatial transcriptomics and proteomics: These approaches allow researchers to map PLCG2 expression and Y1217 phosphorylation in relation to amyloid plaques and other pathological features in brain tissue. This can provide insights into how microglia with different phospho-PLCG2 profiles interact with disease-associated structures.

• Single-cell phospho-proteomics: This technique enables the analysis of PLCG2 phosphorylation patterns in individual cells within heterogeneous populations, revealing cell-type specific responses and potential subpopulations with distinct signaling profiles.

• In vivo microscopy with phospho-specific reporters: Development of fluorescent reporters for Y1217 phosphorylation could allow real-time visualization of PLCG2 activation in living tissues, providing insights into the dynamics of this signaling event in response to various stimuli.

• Mouse models with phospho-specific mutations: Generation of knock-in mice with Y1217F or Y1217E mutations would allow assessment of the specific contribution of this phosphorylation site to microglial function and disease progression in vivo.

• Multi-parametric flow cytometry and mass cytometry (CyTOF): These techniques enable simultaneous analysis of multiple phosphorylation sites, including Y1217, Y753, and Y759, along with other cellular markers, providing a comprehensive view of PLCG2 signaling networks in different cell populations.

• Pharmacological modulation: Development of small molecules that specifically enhance or inhibit Y1217 phosphorylation without affecting other PLCG2 phosphorylation sites would provide valuable tools for investigating the causal relationship between this phosphorylation event and downstream cellular functions.

These advanced methodologies promise to deepen our understanding of PLCG2 Y1217 phosphorylation in complex biological contexts and may lead to novel therapeutic strategies for neurodegenerative and inflammatory diseases.

What strategies can resolve low signal-to-noise ratio when detecting Phospho-PLCG2 (Y1217)?

When researchers encounter low signal-to-noise ratios in Phospho-PLCG2 (Y1217) detection, several optimization strategies can be implemented:

• Enhance stimulation efficiency: For B cells, ensure optimal concentration of anti-IgM antibody (typically 5-20 μg/mL) and appropriate stimulation time (5-10 minutes) . For microglia, use freshly prepared oligomeric Aβ rather than monomeric or fibrillar forms.

• Preserve phosphorylation status: Always include phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate) in lysis buffers. Maintain samples at 4°C during processing and avoid repeated freeze-thaw cycles.

• Optimize antibody concentration: Perform titration experiments to determine the optimal antibody dilution. For Western blot applications, 1:500 - 1:2000 dilutions are typically effective , while for IHC-P applications, 1:50 - 1:200 dilutions may be required .

• Enhance blocking conditions: For Western blot, use 3-5% BSA in TBST rather than milk, as milk contains phosphoproteins that can increase background . For IHC, consider using specialized blocking reagents designed for phospho-epitopes.

• Improve antigen retrieval for IHC: For tissue sections, perform microwave antigen retrieval with 10 mM Tris/EDTA buffer pH 9.0 before IHC staining to enhance epitope accessibility .

• Increase sensitivity of detection systems: For Western blot, use enhanced chemiluminescence (ECL) systems specifically designed for phospho-proteins. For HTRF assays, extend the incubation time to overnight to improve signal development .

• Compare with positive controls: Always include positive controls such as pervanadate-treated Raji cells, which exhibit robust PLCG2 Y1217 phosphorylation .

By systematically addressing these factors, researchers can significantly improve signal-to-noise ratios in Phospho-PLCG2 (Y1217) detection across different experimental platforms.

How can researchers address cross-reactivity concerns with Phospho-PLCG2 (Y1217) antibodies?

Cross-reactivity is a common concern with phospho-specific antibodies. To address potential cross-reactivity of Phospho-PLCG2 (Y1217) antibodies:

• Sequence alignment analysis: Compare the amino acid sequence surrounding Y1217 of PLCG2 (FLYD-Y-T) with similar motifs in other proteins, particularly PLCG1 and other phospholipase family members. This bioinformatic approach can identify potential cross-reactive targets.

• Knockout/knockdown validation: Test the antibody in PLCG2 knockout or knockdown cells. A specific antibody should show minimal signal in these cells compared to wild-type cells after appropriate stimulation.

• Peptide array screening: Screen the antibody against a peptide array containing phosphorylated tyrosine motifs from various proteins to identify potential cross-reactive epitopes.

• Dual detection methods: Confirm phosphorylation events using complementary methods such as mass spectrometry-based phospho-proteomics alongside antibody-based detection.

• Immunoprecipitation followed by Western blot: Immunoprecipitate with a total PLCG2 antibody and then probe with the phospho-specific antibody, or vice versa, to confirm that the detected phosphoprotein is indeed PLCG2.

• Species validation: When working with samples from different species, verify that the phospho-epitope sequence is conserved and that the antibody has been validated in that species. The antibody described in the search results has been validated for human and mouse samples .

• Blocking peptide competition: Perform parallel experiments where the antibody is pre-incubated with the phosphorylated peptide immunogen. This should abolish specific binding while leaving any non-specific binding unaffected.